Michelle Li, Medical Oncologist and Research Fellow at Dana-Farber, shared a post on X:
“New results from DESTINY-Breast11:
- Reduction in overall residual cancer burden with T-DXd-THP vs ddAC-THP
- Consistent across subtype (HR+/HR-) and nodal status (+/-)
- Consistent across many clinical characteristic subgroups
Great addition to data on pCR.”
